celgene - 500 Beiträge pro Seite

[Sinne]

Warum dieser Absturz, wo doch die Ergebnisse gut und die Analystenschätzungen bis 68US$ gehen. Gab es eine Kapitalerhöhung o.ä. Weiß jemand näheres? Wäre für ne Antwort dankbar.

[Mr.Arrogance]

???

fast 2% im plus...

[Sinne]

Versteh ich nicht: Freitag Amiland Schluß 56,12$, Frankfurt 45,40€. Heute Amiland 28,44$ Frankfurt 22,00€. Wo 2% plus?? Sieht eher nach Gratisaktien,Kapitalschnitt o.ä. 1:1 aus

[Damensattel]

#3
Split (25.10.04) 1:2
Quelle:comdirekt Bank

[Boersenkrieger]

Der Split war schon angekündigt... ist normal daß manche anzeigen da noch spinnen kein grund zur unruhe

[js200]

10/26/2004 (13:03 ET) Celgene`s ADHD drug proves safe and effective in children and adults - Datamonitor
10/26/2004 (13:01 ET) Celgene`s ADHD drug proves safe and effective in children and adults - Datamonitor
10/25/2004 (13:03 ET) Celgene receives FDA approval letter for blood cancer drug application - Datamonitor
10/25/2004 (13:01 ET) Celgene receives FDA approval letter for blood cancer drug application - Datamonitor
10/25/2004 (12:05 ET) CELG: Volume Spike; 22% > 20-adsv, Stock +1.35% - Knobias

[js200]

Celgene`s ADHD drug proves safe and effective in children and adults

Tuesday , October 26, 2004 13:03 ET

Oct 26, 2004 (Datamonitor via COMTEX) -- Celgene Corporation`s investigational drug Focalin XR may help adults and children manage ADHD symptoms, according to three separate studies.

The adult study was designed to evaluate the long-term efficacy, safety and tolerability of Focalin XR (dexmethylphenidate HCl) extended release capsules 20mg to 40mg daily. At the end of the double-blind study, Focalin XR, formerly known as Focalin LA, was statistically superior to placebo on both primary comparisons.

At the end of the study`s open label extension, treatment response was evaluated in 103 patients. Patients who switched from placebo to Focalin XR showed significant clinical improvement and patients continuing treatment with Focalin XR continued to show increasing benefits over six months.

Focalin XR was generally well tolerated in adults, with the most frequently reported adverse events including headache, insomnia, and decreased appetite.

Results from one of the pediatric studies show that Focalin XR may help treat Attention Deficit Hyperactivity Disorder (ADHD)symptoms for 12 hours. In both pediatric studies, Focalin XR was also generally well tolerated, with adverse events consistent with those observed in other studies with methylphenidate and dexmethylphenidate.

The division of neuropharmacological drug products at the FDA has accepted for review a new drug application (NDA) submitted by Novartis, to which Celgene has granted an exclusive worldwide license for Focalin XR, excluding Canada. The NDA seeks approval to market Focalin XR for the treatment of pediatric and adult ADHD and has triggered a $7.5 million milestone payment.

Focalin XR is an extended release form of the approved drug, Focalin (dexmethylphenidate HCl), an an advance in single-isomer technology that is formulated by isolating the active d-isomer of methylphenidate. Data suggest that the d-isomer is responsible for the effective management of the symptoms of ADHD.


URL: http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon


Copyright (C) 2004 Datamonitor. All rights reserved


-0-


KEYWORD: United States
SUBJECT CODE: CNS, Other
Pharmaceuticals
Healthcare biotechnology
Healthcare R&D
Novartis AG
Celgene Corporation

[js200]

Wer damals mitgezogen ist, hat schönes Geld verdient


Thema: CELGENE********** KURSZIEL 40 DOLLAR !!!!!!!!!
[Thread-Nr.: 721471]

Tools Informationen zum Thread Navigation
Seitenweise zeigen
In Favoriten aufnehmen (mit Alarm)
Themenübersicht
Aktualisieren

historischer Thread Beiträge:
Gelesen gesamt:
Gelesen heute:
Thread eröffnet von:
Erstes Posting:
Letztes Posting: 108
3098
1
js200
15.04.03 14:19
13.01.04 12:55 AdHocAllgemeinesAlltagsfinanzenAsienAuslandswerteforumAustralienBanken & BrokerBiotechBoardspieleBoardtreffenBreitband/Medien/i-TVBörsenspieleCharttechnikDAXDaytraderDepotbesprechungDeutsche Aktien im FokusDie 50-erEinsteigerforumEx-SAC-ForumFinanzsoftwareFinanzstrategienFonds / InvestmentfondsFundamentalanalyseFuturesGeschlossene FondsGold, Silber, Minen, ExplorerGrüne AktienHedge-FondsHot StocksImmobilienInformationsquellenInsolvenzenInternetInvestmentclubsJunkbondsKanadische WerteKarriereKaufempfehlungKnockoutsKreditelive:traderMakleraktienMDAXNanotechnologieNasdaqNebenwerte DeutschlandNeuemissionenNeuer Markt (hist.)NYSE / AMEXOptionsscheineOsteuropaOTC-BB / PinksheetsPC & TechnikRecht & SteuernRentenSchweizSDAXSparbücher & KontenSport & MotorSüdamerikaTecDAXTelekommunikationUS HotstocksVerkaufsempfehlungVersicherungen + BausparenVorbörsliche Wertew:o Feedbackw:o Newsw:o trading GmbHwallstreet:sofaWesteuropaWirtschaft & Politik (reg.)WährungenZertifikateÖl- und GasstocksÖsterreich


#1 von js200 15.04.03 14:19:13 Beitrag Nr.: 9.178.054 9178054
Dieses Posting: versenden | melden | drucken | historischer Thread CELGENE CORP. DL-,01

Celgene Receives Fast Track Status From FDA for REVIMID(TM) in Myelodysplastic Syndromes
via COMTEX

April 15, 2003

WARREN, N.J., Apr 15, 2003 /PRNewswire-FirstCall via COMTEX/ --

Celgene Corporation (Nasdaq: CELG) announced today that REVIMID(TM) (CC-5013) received fast track designation from the U.S. Food and Drug Administration (FDA) for the treatment of myelodysplastic syndromes (MDS). The FDA grants fast track designation to compounds that may provide a significant improvement in the safety or effectiveness of the treatment for a serious or life-threatening disease. Compounds that receive the designation are also eligible for priority review, which provides for a six-month review of a new drug application by the FDA.

`We are very encouraged by the emerging data on REVIMID as a potential therapy for MDS patients, and based on the data, we are moving REVIMID through the clinical and regulatory development process as quickly as possible to help alleviate the unmet medical needs of MDS patients,`said Sol J. Barer, Ph.D., President and Chief Operating Officer of Celgene Corporation. `We look forward to presenting updated data from our Phase I/II trial of REVIMID in MDS at the International MDS Symposium that will be held May 15-18, 2003 in Paris, France.`

About Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a group of hematologic conditions that affect approximately 50,000 people in the United States. The five types of MDS are refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in formation, and chronic myelomonocytic leukemia. Myelodysplastic syndromes occur when blood cells remain in an immature or `blast`stage within the bone marrow and never develop into mature cells capable of performing their necessary functions. Eventually, the bone marrow becomes filled with blast cells until there is no room for normal cells to develop. According to the American Cancer Society 14,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to five years for the different types of MDS.

REVIMID (CC-5013) is not approved by the FDA and is currently being evaluated in clinical trials for efficacy and safety for future regulatory applications.

Celgene Corporation, headquartered in Warren, New Jersey, is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company`s website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company`s control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company`s filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.

SOURCE Celgene Corporation

Robert J. Hugin, Senior VP and CFO, Celgene Corporation, [phone]

http://www.celgene.com

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200


TECHNISCHER MORGENKOMMENTAR 26. OKTOBER 2004 07:00 Uhr
26.10.2004 | 08:00 @ Uwe Wagner S-T Systemtrade AG (1.751 Zugriffe)
Neben den ohnehin schon recht heftigen Kursverlusten in Europa, fallen die Kursrückgänge in der gestrigen letzten Handelsminute im...




#2 von js200 15.04.03 14:20:15 Beitrag Nr.: 9.178.063 9178063
Dieses Posting: versenden | melden | drucken | historischer Thread CELGENE CORP. DL-,01

http://www.investtech.com/nasdaq/ana/celg.htm

JS200


#3 von js200 15.04.03 14:21:28 Beitrag Nr.: 9.178.071 9178071
Dieses Posting: versenden | melden | drucken | historischer Thread CELGENE CORP. DL-,01

04/15/2003 (07:44 ET) Celgene Receives Fast Track Status From FDA for REVIMID(TM) in Myelodysplastic Syndromes - PR Newswire



04/15/2003 (06:34 ET) Celgene to promote Glaxo`s mulitple myeloma drug - Datamonitor



04/14/2003 (08:15 ET) GlaxoSmithKline`s Alkeran myeloma treatment to be marketed in US by Celgene - AFX News Europe



04/14/2003 (08:15 ET) GlaxoSmithKline`s Alkeran myeloma treatment to be marketed in US by Celgene - AFX News UK



04/14/2003 (08:14 ET) GlaxoSmithKline`s Alkeran myeloma treatment to be marketed in US by Celgene - AFX News Asia



04/14/2003 (07:30 ET) Celgene Signs Strategic Agreement With GlaxoSmithKline to Distribute and Promote ALKERAN(R) (melphalan) - PR Newswire



04/11/2003 (08:55 ET) RATING(o): USB Piper Sets CELG Rating @ Outperform - Knobias



04/10/2003 (10:44 ET) SECTOR(HCR): Biotechs Help Push Sector Lower - Knobias



04/09/2003 (08:00 ET) Celgene to Dominate the Multiple Myeloma Drug Market Through 2011 - PR Newswire



04/08/2003 (07:32 ET) CONF: CELG To Present At Mattison Healthcare Conference @ 10:30 ET - Knobias



04/07/2003 (11:37 ET) VOLUME(-): CELG Volume 32% > 20-adsv, Stock -9.06% - Knobias



04/04/2003 (17:00 ET) Celgene Will Present at Gerard Klauer Mattison Healthcare Conference - PR Newswire



04/03/2003 (09:53 ET) RATING(1): Bear Stearns Initiates CELG Rating @ Peer Perform - Knobias



04/03/2003 (09:51 ET) 52W HIGH: New 52-Wk High for CELG @ $28.420 up1.07% - Knobias



04/03/2003 (07:20 ET) Celgene granted patent covering p38 and JNK pathways - Datamonitor



04/02/2003 (13:42 ET) 52W HIGH: New 52-Wk High for CELG @ $27.970 up4.37% - Knobias



04/02/2003 (07:52 ET) Celgene Strengthens Broad Intellectual Property Estate for Kinase Program With U.S. Patent Covering P38 and JNK Pathways - PR Newswire



04/01/2003 (06:00 ET) EntreMed and Celgene End Standstill Period and Move Towards Strategic Partnership - PR Newswire



03/31/2003 (17:38 ET) New 10-K just released for CELG - Edgar



03/28/2003 (06:16 ET) MEDIA: Today`s Wall Street Journal Mentions CELG - Knobias



03/27/2003 (11:56 ET) VOLUME(+): CELG Volume 20% > 20-adsv, Stock +3.95% - Knobias



03/27/2003 (11:46 ET) 52W HIGH: New 52-Wk High for CELG @ $27.280 up4.68% - Knobias



03/26/2003 (17:02 ET) CONF: CELG To Present At BOA Healthcare Conference @ 19:50 ET - Knobias



03/24/2003 (08:36 ET) Celgene plans further investigation of Thalomid after positive clinical data - Datamonitor



03/24/2003 (08:19 ET) Celgene Will Present at Banc of America Healthcare Conference - PR Newswire

JS200


#4 von js200 15.04.03 14:23:21 Beitrag Nr.: 9.178.091 9178091
Dieses Posting: versenden | melden | drucken | historischer Thread CELGENE CORP. DL-,01

Von Gestern

CELG
CELGENE CORP
25.550
+0.360 +1.43%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 4/8/2003 (6) days ago, when the stock price was 26.300. Since then the stock fell -2.85% .

Today the stock closed higher, at its high (sign of strength) with a lower high and a lower low. The volume is high. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 25.550
Previous Close 25.190
Change +0.360
% Change +1.43%
Volume 1,425,678
Stock Activity
Open 25.160
Day`s High 25.550
Day`s Low 24.720
52 Week High 28.560
52 Week Low 11.500

Stock Price History
3 Month % Change 5.19
6 Month % Change 53.90
12 Month % Change 8.77
Stock Statistics
50 Day Close MA 24.151
200 Day Close MA 20.600
65 Day Volume MA 1,033,766

JS200


#5 von js200 15.04.03 15:45:16 Beitrag Nr.: 9.179.051 9179051
Dieses Posting: versenden | melden | drucken | historischer Thread CELGENE CORP. DL-,01

CELG`s REVIMID Gets Fast Track Designation From FDA

Tuesday , April 15, 2003 08:57 ET

Celgene Corporation (NasdaqNM: CELG) announced that REVIMID(TM) (CC-5013) received fast track designation from the FDA for the treatment of myelodysplastic syndromes (MDS).

The FDA grants fast track designation to compounds that may provide a significant improvement in the safety or effectiveness of the treatment for a serious or life-threatening disease.

Compounds that receive the designation are also eligible for priority review, which provides for a six-month review of a new drug application by the FDA.

JS200

[Mr.Arrogance]

wenn schon, dann doch bitte Thread: 15.07.02 kaufe CELG...

vorsicht vor diesem windigen münchhausen!

[Boersenkrieger]

ich hab das ding irgendwann mal in 2000 oder 2001 ekauft zu 37 Euro und war mal irgendwann 70% im minus jetzt 30% im plus ..ob ich die irgendann mal verkaufen soll

[Mr.Arrogance]

na klar, weg damit...